Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Australia’s G2 Enters Novo Deal Valued At Up To $102M

Feb. 16, 2006

By Jennifer Boggs

Australia’s G2 Enters Novo Deal Valued At Up To $102M

Feb. 16, 2006

By Jennifer Boggs

YM’s Direct Offering Raises $40M For Drug Development

Feb. 15, 2006

By Jennifer Boggs

YM’s Direct Offering Raises $40M For Drug Development

Feb. 15, 2006

By Jennifer Boggs

Replidyne Gets $50M Up Front Through Forest Collaboration

Feb. 14, 2006

By Jennifer Boggs

Replidyne Gets $50M Up Front Through Forest Collaboration

Feb. 14, 2006

By Jennifer Boggs

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 9, 2025
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...
Australia’s Celosia heads toward clinic with gene therapy for ALS
BioWorld
After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that...
Sangamo stock plunges as Pfizer leaves hemophilia partnership
BioWorld
Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.